联合检测脑脊液细胞与游离DNA的MYD88 L265P突变及克隆性可改善原发性中枢神经系统淋巴瘤的诊断
该回顾性队列纳入54例诊断或复发时检测的原发性中枢神经系统淋巴瘤(PCNSL)病例,评估脑脊液细胞沉淀与上清游离DNA中IGH基因克隆性和MYD88 L265P突变检测的贡献,并与细胞学、流式细胞术及IL-10/IL-6定量比较。联合两 compartment 分析时36例(66%)可检出至少一种分子标志物,其中9例(16%)仅cfDNA阳性;综合分子与细胞因子结果,46/54例(85%)脑脊液可检出至少一种淋巴瘤生物标志物。
要点
- 脑脊液细胞沉淀和上清游离DNA联合检测分子标志物可提高PCNSL的生物学诊断率。
- 36例(66%)细胞沉淀和/或上清cfDNA可检出克隆性IGH重排和/或MYD88 L265P突变。
- 综合分子与细胞因子结果,46/54例(85%)脑脊液可检出至少一种淋巴瘤生物标志物。
核心结论
- 在脑脊液细胞沉淀和上清组分中联合评估这些生物标志物可显著改善PCNSL的生物学诊断。
研究设计与样本
- 回顾性队列纳入54例诊断或复发时检测的PCNSL病例,评估脑脊液细胞沉淀与上清中IGH基因克隆性和MYD88 L265P检测,并与细胞学、流式细胞术及IL-10/IL-6定量比较;克隆性评估包括检测部分IGH-DJ重排的新方法。
主要发现
- 克隆性IGH重排和/或MYD88 L265P突变在27例(50%)细胞沉淀和24例(44%)上清cfDNA中检出。
- 联合两组分分析,36例(66%)至少有一种可检测的分子标志物,其中9例(16%)仅cfDNA阳性。
- 细胞学和流式细胞术分别仅7例(13.0%)和9例(17.3%)阳性,而高IL-10水平见于36例(66.7%)。
- 综合分子与细胞因子结果,46/54例(85%)脑脊液可检出至少一种淋巴瘤生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnosis of primary central nervous system lymphoma (PCNSL) is challenging, and although brain biopsy remains the gold standard, cerebrospinal fluid (CSF) constitutes a less invasive source of lymphomatous biomarkers. In a retrospective cohort of 54 PCNSL cases tested at diagnosis or relapse, we evaluated the contribution of immunoglobulin heavy chain (IGH) gene clonality and MYD88 L265P detection on both CSF cell pellets and supernatants, in comparison with cytology, flow cytometry, interleukin (IL)-10 and IL-6 quantification. Clonality assessment included a new assay to detect partial IGH-DJ rearrangements. Clonal IGH rearrangements and/or MYD88 L265P mutation were detected in 27 (50%) cell pellets and 24 (44%) supernatant cell-free (cf) DNA. Combining analyses on both compartments, 36 (66%) cases had at least one detectable molecular marker, present only in cfDNA for 9 (16%) of them. While cytology and flow cytometry were positive in only 7 (13.0%) and 9 (17.3%) cases respectively, high IL-10 levels were observed in 36 (66.7%) cases. Overall, taking into account molecular and cytokine results, 46/54 (85%) cases had at least one lymphomatous biomarker detectable in the CSF. These results show that this combination of biomarkers evaluated on both cell pellet and supernatant CSF fractions improves significantly the biological diagnosis of PCNSL.
引用
- Bravetti C, Degaud M, Armand M, et al. Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma. Br J Haematol. 2023. PMID: 36941788. doi:10.1111/bjh.18758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。